SG11201911512SA - Agent for preventing or treating brain atrophy - Google Patents

Agent for preventing or treating brain atrophy

Info

Publication number
SG11201911512SA
SG11201911512SA SG11201911512SA SG11201911512SA SG11201911512SA SG 11201911512S A SG11201911512S A SG 11201911512SA SG 11201911512S A SG11201911512S A SG 11201911512SA SG 11201911512S A SG11201911512S A SG 11201911512SA SG 11201911512S A SG11201911512S A SG 11201911512SA
Authority
SG
Singapore
Prior art keywords
preventing
agent
treating brain
brain atrophy
atrophy
Prior art date
Application number
SG11201911512SA
Other languages
English (en)
Inventor
Hiroshi Kobayashi
Yoshihiko Matsumoto
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of SG11201911512SA publication Critical patent/SG11201911512SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201911512SA 2017-06-02 2018-06-01 Agent for preventing or treating brain atrophy SG11201911512SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017109885 2017-06-02
JP2017128472 2017-06-30
JP2017145100 2017-07-27
PCT/JP2018/021223 WO2018221729A1 (ja) 2017-06-02 2018-06-01 脳萎縮予防または治療剤

Publications (1)

Publication Number Publication Date
SG11201911512SA true SG11201911512SA (en) 2020-01-30

Family

ID=64455855

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911512SA SG11201911512SA (en) 2017-06-02 2018-06-01 Agent for preventing or treating brain atrophy

Country Status (15)

Country Link
US (1) US11951092B2 (ja)
EP (1) EP3632431A4 (ja)
JP (2) JP7282028B2 (ja)
KR (1) KR20190137936A (ja)
CN (3) CN116473962A (ja)
AU (1) AU2018276638B2 (ja)
BR (1) BR112019024851A2 (ja)
CA (1) CA3067453C (ja)
IL (1) IL270922A (ja)
MX (1) MX2019014310A (ja)
NZ (1) NZ759585A (ja)
RU (1) RU2759727C2 (ja)
SG (1) SG11201911512SA (ja)
WO (1) WO2018221729A1 (ja)
ZA (1) ZA201907973B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ759585A (en) * 2017-06-02 2022-02-25 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating brain atrophy
WO2018221732A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アミロイドβ蛋白質量減少剤
NZ759647A (en) 2017-06-02 2022-02-25 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating spinocerebellar ataxia
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
US11548878B2 (en) 2017-10-30 2023-01-10 Fujifilm Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2302808C (en) 1997-09-05 2010-05-18 Human Genome Sciences, Inc. 50 human secreted proteins
GB9824207D0 (en) 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
BRPI0213393B8 (pt) 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
AU2004229283B2 (en) 2003-04-17 2009-02-05 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
SI2011796T1 (sl) * 2006-04-26 2015-02-27 Toyama Chemical Co., Ltd. Induktor nevrogeneze ali terapevtska uäśinkovina proti nevropatiji, vsebujoäśa derivat alkilnega etra ali sol le-tega
NZ587532A (en) 2008-03-04 2012-07-27 Vernalis R&D Ltd Azetidine derivatives for inhibition of faah activity
FR2934596B1 (fr) 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
NO2419104T3 (ja) 2009-04-13 2018-04-07
JP5808319B2 (ja) 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα7ニコチン酸受容体を用いた認知障害の治療
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
CN104159583B (zh) * 2012-02-22 2018-04-13 富山化学工业株式会社 含有1‑(3‑(2‑(1‑苯并噻吩‑5‑基)乙氧基)丙基)氮杂环丁烷‑3‑醇或其盐的固体药物组合物
AU2013292519B2 (en) 2012-07-19 2017-12-07 Drexel University Sigma receptor ligands for modulating cellular protein homeostasis
EP2903980B1 (en) 2012-10-01 2017-07-19 F. Hoffmann-La Roche AG Benzimidazoles as cns active agents
LT3100725T (lt) * 2014-01-31 2020-08-10 Fujifilm Toyama Chemical Co., Ltd. Reabilitacijos poveikį po nervo pažeidimo sustiprinanti priemonė, apimanti alkileterio darinį arba jo druską
WO2015163318A1 (ja) 2014-04-25 2015-10-29 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
WO2016051799A1 (ja) 2014-10-01 2016-04-07 学校法人同志社 2-アミノヒドロキノン誘導体及びタウ凝集阻害剤
SG11201705727TA (en) 2015-02-02 2017-08-30 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
US20160324851A1 (en) 2015-05-07 2016-11-10 Axovant Sciences, Ltd. Methods of treating a neurodegenerative disease
EP3308782B1 (en) 2015-06-11 2022-01-19 Toyama Chemical Co., Ltd. Sigma-receptor binding agent
KR102703879B1 (ko) 2015-12-25 2024-09-05 후지필름 도야마 케미컬 가부시키가이샤 1-(3-(2-(1-벤조티오펜-5-일)에톡시)프로필)아제티딘-3-올 또는 그 염을 포함하는 정제
NZ759585A (en) * 2017-06-02 2022-02-25 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating brain atrophy
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
NZ759647A (en) 2017-06-02 2022-02-25 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating spinocerebellar ataxia
WO2018221731A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 タウオパチー予防または治療剤
WO2018221732A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アミロイドβ蛋白質量減少剤
US11548878B2 (en) 2017-10-30 2023-01-10 Fujifilm Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Also Published As

Publication number Publication date
CN116492335A (zh) 2023-07-28
CN110709078A (zh) 2020-01-17
EP3632431A1 (en) 2020-04-08
AU2018276638B2 (en) 2021-04-08
NZ759585A (en) 2022-02-25
CN116473962A (zh) 2023-07-25
JPWO2018221729A1 (ja) 2020-04-09
RU2759727C2 (ru) 2021-11-17
IL270922A (en) 2020-01-30
US20200215030A1 (en) 2020-07-09
ZA201907973B (en) 2022-03-30
MX2019014310A (es) 2022-06-10
RU2019138166A (ru) 2021-07-09
JP7282028B2 (ja) 2023-05-26
WO2018221729A1 (ja) 2018-12-06
CA3067453C (en) 2021-11-23
EP3632431A4 (en) 2020-06-03
US11951092B2 (en) 2024-04-09
KR20190137936A (ko) 2019-12-11
CA3067453A1 (en) 2018-12-06
JP2023053337A (ja) 2023-04-12
RU2019138166A3 (ja) 2021-07-09
BR112019024851A2 (pt) 2020-06-09
AU2018276638A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
GB201715639D0 (en) Compositions for wound treatment
SG11201705767PA (en) Agent for preventing and/or treating amyotrophic lateral sclerosis
ZA201907973B (en) Agent for preventing or treating brain atrophy
IL262825A (en) Tetrahydropyridine and tetrahydropyrimidine substances, preparations containing them and their use for pain treatment
GB201709402D0 (en) Compounds for treating t-pll
IL271256A (en) Preparations and methods for the treatment of teopathy
GB2567616B (en) Treatment method
ZA201907975B (en) Agent for preventing or treating tauopathy
ZA201906047B (en) Compounds for treating tuberculosis
GB2571601B (en) Treatment method
ZA201907974B (en) Agent for preventing or treating spinocerebellar ataxia
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
IL291266A (en) Preparations and methods for treating infections
ZA201907283B (en) Compositions, devices and methods for treating autism
PL3426237T3 (pl) Sposób leczenia zaniku mózgu
GB202214988D0 (en) Compositions and methods for preventing or treating nephrolithiasis
SG11202001806TA (en) Treatment method
IL270867A (en) Treatment method
SG11202004642YA (en) An agent for treating nocturnal pollakiuria
IL271967A (en) Methods for treating congenital hypersecretion of insulin
EP3432884A4 (en) COMBINATIONS FOR THE TREATMENT OF PAIN
SG11202103619QA (en) Methods for treating or preventing skin conditions
RS62891B1 (sr) Kompozicija za lečenje konstipacije
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB201711677D0 (en) Combination treatment